Richter has announced the launch of Terrosa (teriparatide) in Europe, a biosimilar of Eli Lilly’s Forsteo (teriparatide).
Both products are approved in adults for the same indications; the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. They are also approved for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.
The drugs also demonstrated a a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures in post-menopausal women.
The European Commission (EC) already approved the biosimilar in 2017 following the adoption of a positive opinion by the Committee for Medicinal Products for Human Use (CHMP). Both decisions were made based on data derived from studies that demonstrated the Richter drug’s biosimilarity with Forsteo.
The company announced that it is “excited” about the introduction, as it “reflects our commitment to scientific programmes linked to complex medications such as biologicals. Biosimilars will increase choice and access for patients in the European countries, while providing potential cost savings to healthcare systems. We look forward to bringing more high quality and affordable biosimilar products to the market”, according to Gábor Orbán, chief executive officer of the company.
